Locations:
July 13, 2026/Cancer/News & Insight

New ASCO Guidelines Help Clinicians Navigate Rapid Shifts in Thyroid Cancer Treatment

Expert recommendations introduce use of targeted agents

Thyroid cancer illustration

The tremendous growth in understanding of the molecular basis of thyroid cancer has brought new opportunities for targeted treatment. Depending on the type of thyroid cancer and mutation involved, patients may have the option of targeted therapy, multikinase inhibitors or immunotherapy in addition to more traditional surgical or radioiodine options. These emerging treatments are reshaping treatment sequencing and disease management.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

With myriad options available, it can be confusing for clinicians to know which treatment is most appropriate. In this quickly changing therapeutic landscape, the American Society of Clinical Oncology (ASCO) brought together a multidisciplinary panel to create new recommendations for systemic treatment of the disease. This included recommendations for treating well-differentiated, differentiated high-grade or poorly differentiated, anaplastic and medullary thyroid cancer

“We’re now able to target molecular aberrations and treat thyroid cancer in ways that we never could in the past,” says ASCO panel expert Joseph Scharpf, MD, Director of Head & Neck Endocrine Surgery at Cleveland Clinic. “Traditionally, treatment involved surgery or radioactive iodine but that has shifted. Surgeons, radiation oncologists, medical oncologists and endocrinologists need evidence-based recommendations about the various agents and targets now available and how best to coordinate care.”

Most notably, the panel emphasized that not all immunotherapy is right for each type of thyroid cancer. For example, pembro immunotherapy isn’t intended for patients with medullary thyroid cancer.

The guidelines also highlighted the importance of molecular testing for patients with advanced or aggressive thyroid cancer, ideally in the upfront setting. This testing can help identify potential targeted treatments for many patients, such as those with a RET alteration. Additionally, the panel raised awareness about agents for controlling distant metastases, even for some of the most challenging cases such as anaplastaic thyroid cancer.

Advertisement

Patients with this fast-moving disease often present in the emergency room with trouble breathing or swallowing. “Traditionally, patients with anaplastic thyroid cancer had dismal outcomes, but now agents like dabrafenib and trametinib can target BRAF and MEK mutations in roughly half of these patients,” says Dr. Scharpf. “Together with pembro immunotherapy, many patients are seeing remarkable results. We often treat aggressive disease in my practice, and this approach has been a game changer.”

As noted in the guidelines, treatment selection and sequencing decisions are best made with a multidisciplinary tumor board. Radioiodine still plays an integral role in treating thyroid cancer, but there is a move towards personalizing its use. Some patients with more favorable disease profiles may not need this therapy.

In addition, while surgery is still the standard of care, targeted agents can be used in some instances to lessen the degree of surgical intervention needed. This is particularly beneficial if the surgery involves risk to nerves or the windpipe.

In addition to helping draft the ASCO guidelines, Cleveland Clinic Cancer Institute also participates in research to study potential new thyroid cancer therapies. The Institute collaborated on a recently published study of anaplastic thyroid cancer treatment, and recently entered a trial of the oral tyrosine kinase inhibitor zanzatinib for treating invasive thyroid cancer.

Advertisement

Related Articles

Dr. Gerds
November 20, 2026/Cancer/Blood Cancers

Patient Case Study: Rusfertide Improves Quality of Life with Polycythemia Vera

Therapy eliminates the need for phlebotomies

Dr. Kevin Elias in the lab
November 18, 2026/Cancer

Spotting Ovarian Cancer Before it Starts

Inside Cleveland Clinic’s Quest for an Ovarian Cancer Screening Tool

Dr. Anwer and colleagues
November 12, 2026/Cancer/Blood Cancers

FDA Approval of Iberdomide Marks Historic Milestone in Multiple Myeloma

CELMoD therapy receives approval based primarily on measurable residual disease

Dr. Dedousis
November 2, 2026/Cancer/Podcast

Expanding Germline Genetic Testing in Oncology (Podcast)

Are we missing patients?

Dr. Hanlee Chung
October 29, 2026/Cancer/Podcast

Redefining Resectability in Advanced Rectal Cancer (Podcast)

Expanding treatment options for patients with advanced and recurrent rectal cancer

Patient and healthcare providers
October 28, 2026/Cancer/Patient Support

Desire for Preventative Screening is Strong Among People Experiencing Homelessness

Study analyzes creative approaches to support people facing housing insecurity

AI tech
October 26, 2026/Cancer/Innovations

AI Task Force Develops Unified Strategy to Integrate Tech Innovations

Evaluating AI initiatives and their impact on operations and care delivery

DNA test
October 23, 2026/Cancer/News & Insight

Early Genetic Testing Linked to Bilateral Mastectomy in Young BRCA Carriers with Breast Cancer

Study reinforces the importance of genetic testing prior to local therapy decisions

Ad